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ABSTRACT The avian reticuloendotheliosis virus T con-
tains within its genome the oncogene rel. The expression of this
gene is responsible for the induction of lymphoid tumors in
birds. Recently, the rel gene was shown to be related to the p50
DNA binding subunit of the transcription factor complex
NF-KB. Binding sites for the NF-#cB complex are found in the
enhancer regions of a number of genes, including the immu-
noglobulin K gene and the human immunodeficiency virus long
terminal repeat. In this communication we identify an activity
from avian reticuloendotheliosis virus T-transformed avian
lymphoid cells that binds in an electrophoretic-mobility-shift
assay to an NF-KB binding site from the K enhancer. This
activity contains proteins immunologically related to rel, as
detected by polyclonal and monoclonal antibodies directed
against v-rel. In a DNA affinity precipitation assay using the
NF-KB site from the human immunodeficiency virus long
terminal repeat, v-rel and several other proteins were identi-
fied. These data suggest that oncogenic transformation by v-rel
is the result of an altered pattern of gene expression.
Infection of birds with the avian reticuloendotheliosis virus T
(REV-T) results in a fatal lymphoma within days after infec-
tion (1). In vitro REV-T is also able to transform avian
lymphoid cells (2). v-rel, the oncogene harbored by REV-T,
is a truncated form of its cellular homologue, c-rel, that lacks
two amino acids at the amino terminus and 118 amino acids
at the carboxyl terminus (3, 4). The protein product of the
v-rel gene p59v-rel is a phosphoprotein that is found in both the
nucleus and cytoplasm in transformed lymphoid cells (5). We
(5) and others (6) have demonstrated that v-rel is part ofa high
molecular mass complex in the infected cell that includes
cellular proteins of 124 kDa, 115 kDa, and 36 kDa.
The rel gene was shown to be related to the Drosophila
embryonic polarity gene dorsal. The extent of homology in a
295-amino acid stretch at the amino terminus is 75% when
conservative amino acid changes are taken into account (7).
The carboxyl termini are unrelated. Reminiscent of v-rel, the
dorsal protein is also found either in the cytoplasm or
nucleus. However, the localization of dorsal is controlled by
positional effects within the developing embryo and car-
boxyl-terminal sequences (8). The recent cloning of the p50
DNA binding subunits ofthe transcription factors NF-KB and
KBF-1 also revealed homology with rel (9, 10). As with
dorsal, the homology extends over -334 amino acids at the
amino terminus. Biochemical evidence suggests further sim-
ilarities between these proteins. NF-KB is found in the
cytoplasm and nucleus and also associates in complex with
other cellular proteins (11).
Functional studies support the suggestion that NF-KB,
dorsal, and rel are closely related. All three proteins are able
to modulate transcription from a variety of promoters (11-
13). In addition, the c-rel protein contains a carboxyl-terminal
transcriptional activation domain as shown by fusion to LexA
or GAL4 DNA binding sequences (14, 15). Thus these data
imply that rel is involved in the control of transcription.
The biochemical and functional similarities of rel, dorsal,
and NF-KB prompted us to examine the ability of v-rel to bind
to DNA, specifically to an NF-KB binding site. In this
communication we demonstrate by an electrophoretic-
mobility-shift assay (EMSA) that nuclear and cytosolic ex-
tracts from a REV T-transformed avian lymphoid cell line
(NPB4) contain an activity that is immunologically reactive
with both polyclonal and monoclonal antibodies directed
against v-rel and that binds to a double-stranded oligonucle-
otide containing an NF-KB binding site. This activity consists
of a set of proteins including v-rel, as determined by a DNA
affinity precipitation (DNAP) assay (16) and two-dimensional
(2D) gel analysis of proteins immunoprecipitated from NPB4
extracts with a monoclonal antibody directed against v-rel.
MATERIALS AND METHODS
Cells. NPB4 cells are a REV-T-transformed cell line (de-
rived by infection of avian bone marrow) that express low
levels of IgM and B lymphoid-specific cell surface markers
(L. Morrison, personal communication; ref. 2). The cells
were grown as described (5).
EMSA. Nuclear or S100 extract (7.5 ,/g) from NPB4 cells,
prepared as described by Dingham et al. (17), was incubated
on ice for 15 min in the presence of 0.5 gg of salmon sperm
DNA and incubation buffer [final concentrations after DNA
oligonucleotide addition: 10 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM dithiothreitol, 1 mM EDTA, 5% (vol/vol)
glycerol, and 3 mM dGTP], followed by the addition of
10,000-20,000 cpm of labeled oligonucleotide (with or with-
out unlabeled competitor) and incubation at room tempera-
ture for 20 min. The reactions were performed in a final
volume of 25 ul and samples were run on 6% native poly-
acrylamide gels at 200 V in TBE (25 mM Tris base/22 mM
boric acid/0.25 mM EDTA, pH 8.0) at 4°C.
Oligonucleotides and Labeling Procedure. Oligonucleotides
contained the following sequences: NF-KB, 5'-AGCTTCAA-
CAGAGG-GGACTTTCCGAGAGGCTCGAG-3', and the
complementary strand, 5'-AATTCTCGAGCCTCTCG-
GAAAGTCCCCTCTGTTGAA-3'. NF-KB(M) oligonucleo-
tides are identical to the NF-KB oligonucleotides except that
the underlined nucleotide was changed from a guanine to a
cytosine (and vice versa for the complementary strand). This
sequence has been reported to have a >100 times lower
affinity for NF-KB (18). The MYB oligonucleotide, kindly
provided by Joe Lipsick (State University of New York at
Stony Brook), contained the sequence 5'-GATCCAAATA-
ACGGAAAAGATCT-3', and the complementary strand was
5'-GATCAGATCTTTTCCGTTATTTG-3'. The HIVEN3c
Abbreviations: REV-T, reticuloendotheliosis virus T; EMSA, elec-
trophoretic-mobility-shift assay; DNAP, DNA affinity precipitation;
2D, two dimensional.
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oligonucleotide contained the sequence 5'-AGGGACY1'-lC-
CGCTGGGGAC'lT-CCAG-3' repeated once and annealed
with the complimentary strand. The HIVEN3m mutant oligo-
nucleotide contained the sequence 5'-ACTCACTTTCCGCT-
GCTCACTTTCCAG-3' repeated once and annealed to the
complimentary strand. The HIVENc and -m oligonucleotides
were used in the DNAP assay described below. The probes
used for mobility-shift analyses were labeled using
[a-32P]dATP, [a-32P]dGTP, [a-32P]dCTP, and the Klenow
fragment of DNA polymerase I.
Antibodies and Western Blots. Rabbit polyclonal antibody
SB66 is directed against a trpE-rel fusion protein (pJH12 rel),
which has been described (5, 19). P1 represents the pJH12 rel
fusion protein. P2 is a nonoverlapping trpE-rel fusion pro-
tein.
Production of Monoclonal Antibodies. The polyclonal anti-
body SB66 was covalently linked to protein A-Sepharose by
standard procedures (20). This matrix was incubated with
NPB4 cell extract and bound rel protein was eluted at pH 11.5
in 20 mM ethanolamine. BALB/c mice were inoculated with
50 ,ug of affinity-purified rel protein for the production of
monoclonal antibodies. Standard protocols were followed for
injection, fusion of spleen cells, and screening of hybridomas
(20). Hybridoma supernatants were screened for reactivity to
p59v-rel. Western blots were performed essentially as de-
scribed (21).
DNAP Analysis. NPB4 cells were grown as described (5)
and labeled with Tran35S-label (ICN) at 1 mCi/ml (1 Ci = 37
GBq). Immunoprecipitation was carried out as described (5)
and samples were prepared for analysis in 2D gels as de-
scribed (16). Cells were lysed in 600 /l4 of DNAP buffer as
reported (16). The final KCl concentration for extraction was
250 mM and the final NaF concentration was 50 mM. DNAP
binding assays were conducted at 75 mM KCl and the same
KCl concentration was used for rinsing the streptavidin-
agarose-biotinylated oligonucleotide complex. The appropri-
ate biotinylated oligonucleotide (HIVEN3c or HIVEN3m
synthesized by the Cold Spring Harbor Laboratory oligonu-
cleotide facility) at 100 pmol and a 40-fold mass excess of
poly(dI-dC) (Pharmacia) were used per DNAP assay. Beads
were rinsed four times with 400 ,ul ofDNAP buffer containing
75 mM KCl and 5 mM NaF and then rinsed once with 50 ILI
of DNAP buffer without KCl or NaF. All samples were
prepared for 2D gels by addition of 1 /l of a DNase/RNase
solution, incubation on ice for 2 min, addition of 40 /4u of a
SDS solution, and incubation at 370C for 4 min. Each sample
was lyophilized and resuspended in 40 of SB 2D gel sample
buffer. The solutions above were as described (16). The 2D
gels consisted of a pH 3.5-10 isoelectric first-dimension gel
and a 10% acrylamide second-dimension gel.
RESULTS AND DISCUSSION
NF-KB Binding Activity in NPB4 Cells. To determine if the
REV-T-transformed cell line NPB4 contained an activity that
could bind to the NF-KB binding site, nuclear extracts were
prepared from NPB4 cells and used in the EMSA (22). A
radioactively labeled oligonucleotide containing a single
NF-KB site was used as a probe in this analysis. Two major
protein-DNA complexes (B1 and B2) were observed after
incubation of the oligonucleotide with nuclear extract (Fig.
LA, lane 1), suggesting that the NPB4 cell line did indeed
contain an NF-KB-like binding activity. The relationship
between B1 and B2 is not clear at present since the EMSA
precludes an analysis of the protein composition of B1 and B2.
To demonstrate the specificity of the B1 and B2 complexes for
the NF-KB oligonucleotide, competition experiments were
performed. Unlabeled oligonucleotides containing the wild-
type NF-KB site, a mutant NF-KB site containing a single
point mutation, or a myb binding site were used to compete
with labeled NF-KB oligonucleotides. The wild-type oligo-
nucleotide competed effectively at a 100-fold molar excess
(Fig. LA, lanes 2-4). The mutant NF-KB oligonucleotide,
which has been reported to have an -100 times lower affinity
for NF-KB (18), competed moderately at a 1000-fold molar
excess (Fig. LA, lanes 5-7). In contrast, the oligonucleotide
containing the myb binding site did not compete when
present at a 1000-fold molar excess (Fig. LA, lanes 8-10).
To investigate whether the specific complexes (B1 and B2)
contained the rel protein, an EMSA was performed in the
presence of polyclonal antibody SB66 directed toward the rel
protein. A new slower migrating complex (B*) and a corre-
sponding decrease in the B1 and B2 protein-DNA complexes
was observed in the presence of SB66 but not preimmune
serum (Fig. iB, lanes 3 and 4). To demonstrate the specificity
of this interaction, protein-DNA complexes were incubated
with antiserum SB66 in the presence of the trpE-rel fusion
protein (P1) (5, 19) used to generate the antibody. The slower
migrating species B* was no longer detectable (Fig. 1B, lane
5). Incubation of the protein-DNA complexes with antibody
SB66 and an unrelated trpE-rel fusion protein had no effect
on the formation of the B* complex (Fig. 1B, lane 6). These
results suggested that the protein(s) interacting with the
NF-KB oligonucleotide probe were antigenically related to
rel. It was possible that the polyclonal antibody recognized
cross-reactive proteins related to the NF-KB binding pro-
teins. To demonstrate the specificity of the SB66 polyclonal
antibody, Western blot analysis of NPB4 cell extract was
performed. The nitrocellulose filter containing NPB4 cell
lysate was probed with affinity-purified SB66. As can be seen
in Fig. 1D, lane 3, the antibody recognizes p68cI, p59v-relC
and several other proteins in the molecular mass range of
40-50 kDa in NPB4 cells. These proteins may represent
proteolytic cleavage products of rel or cross-reactive related
proteins. Therefore, to demonstrate that v-rel was at least one
component in the protein-DNA complexes, two v-rel-
specific monoclonal antibodies were also tested for their
ability to reduce the mobility of the protein-DNA com-
plex(es) (Fig. 1C, lanes 3 and 4). The specificity ofthe anti-rel
monoclonal antibodies 6 and 33 is shown in Fig. 1D, lanes 1
and 2. When NPB4 cell extracts were subjected to Western
blot analysis and probed with monoclonal antibodies 6 and
33, these antibodies recognized only p59v-rel. Each monoclo-
nal antibody was able to reduce the mobility of the protein-
DNA complexes to a position equivalent to B* (Fig. 1C, lanes
3 and 4), supporting the conclusion that v-rel is at least one
of the constituents binding to the NF-KB site. As can be seen,
incubation with the monoclonal antibodies does not dramat-
ically reduce bands B1 or B2. This may be due to one of
several possibilities. The titers or affinity of monoclonal
antibodies 6 and 33 are significantly lower than SB66, per-
haps accounting for the weak intensity of the B* band
observed. Alternatively, the monoclonal antibodies may rec-
ognize only a subset ofthe protein-DNA complexes. It is also
possible that the epitopes recognized by the monoclonal
antibodies are partially masked in the protein-DNA com-
plexes. Because SB66 also recognizes c-rel, it is conceivable
that some of the binding activity reactive with the SB66, but
not the monoclonal antibodies, is c-rel. However, prelimi-
nary examination of the binding activity from the NPB4 cell
line with a c-rel-specific peptide antibody did not reveal any
detectable c-rel-specific binding activity (data not shown).
Thus these data suggest that nuclear extracts from trans-
formed lymphoid cells possess an NF-KB binding activity that
contains v-rel. Incubation with an unrelated monoclonal
antibody, M4, specific to avian immunoglobulin (IgM, ref.
23), did not result in the appearance of a B* band (Fig. 1C,
lane 5).
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FIG. 1. EMSA utilizing nuclear extracts from NPB4 cells and a double-stranded oligonucleotide containing an NF-KB binding site sequence.(A) EMSA in the presence of unlabeled competitor oligonucleotides. The molar excess of competitor is indicated in parentheses above the
respective lanes. Lane 1 does not contain added competitor. Bands F and B are free and bound probe DNA, respectively. NF-KB, MYB, and
NF-KB(M) are unlabeled double-stranded competitor oligonucleotides containing a wild-type NF-KB binding site, a myb binding site, or an
NF-KB site with a single-point mutation, respectively. (B) EMSA done in the absence of nuclear extract (lane 1) or in the presence of 7.5 mg
of nuclear extract (lanes 2-6). DNA binding reactions were followed by incubation with preimmune sera (lane 3), polyclonal immune serum SB66
directed toward the rel protein (lane 4), immune serum in the presence of P1, a trp E-rel fusion protein used to immunize the rabbits in the
generation of antiserum SB66 (lane 5), or immune serum in the presence of P2, an unrelated trpE-rel fusion protein (lane 6). Bands F and B
are free and bound probe, respectively. B* indicates a band with retarded migration after the addition of polyclonal antibody directed to the
rel protein. (C) EMSA of extracts incubated with polyclonal antisera SB66 (lane 2) or monoclonal antibodies (MAb) 6 and 33 (lanes 3 and 4,
respectively). Lane 5 contains monoclonal antibody M4, specific to avian immunoglobulin, as a negative control (23). Lane 1 contains no added
immunoglobulin. (D) Western blot of lysates from NPB4 cells probed with monoclonal antibody 6 (lane 1), monoclonal antibody 33 (lane 2),
or polyclonal antibody SB66 (lane 3). Bands p59 and p68 identify avian v-rel and c-rel proteins, respectively.
NF-KB was originally identified as a lymphoid-specific
nuclear activity capable of binding to the immunoglobulin K
enhancer (24). It was subsequently demonstrated to exist
ubiquitously in an inactive cytoplasmic form (for review, see
ref. 11). Treatment of cells with phorbol esters causes the
dissociation of cytoplasmic NF-KB from an inhibitor protein
(IKB) resulting in translocation to the nucleus and an increase
in NF-KB DNA binding activity (25, 26). Our previous
biochemical analyses of the NPB4 cell line have shown that
80-90% of the v-rel protein is present in the cytoplasm (5).
Therefore, we were interested in comparing the binding
activity of the cytoplasmic and nuclear extracts from the
NPB4 cell line to an oligonucleotide containing the NF-KB
site.
Two protein-DNA complexes (Bc1 and Bc2) were observed
after incubation of the oligonucleotide with the cytoplasmic
(S100) extract (Fig. 2A, lane 1). Competition analysis was
then performed to determine the specificity of the Bc1 and B02
complexes for the NF-KB oligonucleotide. The wild-type
oligonucleotide competed for both Bc1 and Bc2 effectively at
100-fold molar excess (Fig. 2A, lanes 2-4). The oligonucle-
otide containing the mutant NF-KB site competed for the Bc2
complex at a 100-fold molar excess (Fig. 2A, lanes 5-7),
although less effectively than the wild-type oligonucleotide.
Oligonucleotides containing the myb binding site competed
for Bc2 at a 1000-fold molar excess. The B_1 complex was not
competed significantly by the myb or mutant NF-KB oligo-
nucleotides (Fig. 2A, lanes 5-10).
To determine whether either B01 or Bc2 complexes con-
tained rel or rel-related proteins, an EMSA was performed.
Protein-DNA complexes were incubated with the affinity-
purified SB66 antisera after the DNA binding reaction. A
band with reduced mobility (B*) was observed after incuba-
tion with the antibody, with a concommitant decrease in the
B01 band, suggesting that this complex, but not the Bc2
complex, contained proteins recognized by the anti-rel anti-
sera (Fig. 2B, lanes 1 and 2). Bc1 appears to comigrate with
the nuclear band B2 (Fig. 2B, lanes 3 and 4) and both are
reactive with antibody SB66. However, it is not clear from
this analysis that these two comigrating bands represent the
same protein-DNA complex. Analysis with the monoclonal
antibodies 6 and 33, which are only reactive to the v-rel
protein, also resulted in a band with reduced mobility (data
not shown). When cell equivalent amounts of NPB4 nuclear
and cytoplasmic extract were compared by EMSA for bind-
ing to the NF-KB oligonucleotide, approximately equivalent
binding activity was observed (data not shown). However,
the majority of SB66-reactive proteins (predominantly v-rel;
ref. 5) are in the cytoplasm, suggesting that the specific
binding activity of the cytoplasmic proteins is lower than that
from the nuclear fraction.
DNAP Assay. The EMSA data presented are suggestive that
v-rel is at least part of the protein complex that binds to the
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NF-KB site. To show definitively that v-rel was part of the
protein complex binding to the NF-KB site, a microscale
DNAP assay was employed (16). Whole-cell extracts, pre-
pared as described (16), were incubated with biotinylated
oligonucleofides containing either wild-type (HIVEN3c) or
mutant (HIVEN3m) NF-KB binding sites from the human
immunodeficiency virus long terminal repeat. Proteins bound
to the probes were analyzed by 2D gel electrophoresis. Fig. 3
is an example of such an analysis. Only the relevant portions
Bc-2-* z-Bc -
BC-hid -B2
-B1
F-
1 2 3 4
FIG. 2. EMSA utilizing cytoplasmic
(S100) extracts from NPB4 cells and a
double-stranded oligonucleotide contain-
ing an NF-KB binding site sequence. (A)
EMSA in the presence of unlabeled com-
petitor oligonucleotides. Nomenclature
is identical to that for Fig. LA. (B) EMSA
of cytoplasmic (15 Mg) and nuclear (7.5
Mg) NPB4 extracts in the presence (lanes
2 and 4) or absence (lanes 1 and 3) of
antiserum SB66. Nuclear and cytoplas-
mic (S100) extracts were prepared as
described (17). Bands F, B, and Bc are
free and bound probe, respectively. Band
B* is a probe with reduced mobility after
the addition of antibody specific to the rel
protein.
of the gels (i.e., proteins of 40-65 kDa) are shown from this
experiment. As can be seen in Fig. 3B, several proteins are
identified that bind to the wild-type (HIVEN3c) but not to the
mutant oligonucleotide (Fig. 3A, HIVEN3m oligonucleotide).
These include the circled and bracketed spots. This result is
consistent with previous reports that have identified a number
of cellular proteins that bind to the NF-cB site in the DNAP
assay (16, 27, 28), including the HIVEN86A protein, which
has recently been shown to correspond to human c-rel (29).
!IV NF-KB Mutant Oligo
a v
A
(,e0[
e 59v-re/
fB
Cr
L I
0
A
HIV NF-Kc1 Wild-type Oligo
A "s#
*
p59V-reI
@8
c
[ 4b
I [di1
*a
B
FIG. 3. 2D gel comparison ofhuman immunodeficiency virus enhancer binding proteins to proteins in an anti-rel immune complex. (A) DNAP
analysis using the HIVEN3m (GGG to CTC mutant oligonucleotide). (B) DNAP analysis using the HIVEN3c oligonucleotide. (C) Anti-rel
immunoprecipitation using monoclonal antibody 33, which recognizes v-rel but not proteins of 40-50 kDa. (D) Immunoprecipitation with HAT
medium (no added monoclonal antibody). p59V1-l is identified in B and C. Proteins in B that specifically interact with the human
immunodeficiency virus type 1 enhancer core oligonucleotide are designated by letter. Proteins in C that are members of the anti-rel immune
complex are designated by letter. Exposure offluorographed gels was 20 days at -70oC. Only relevant regions of the gels (i.e., proteins of40-65
kDa) are shown in this figure. (E) NPB4 protein-DNA complexes were formed with oligonucleotides HIVEN3c or HIVEN3m, as described
above, and subjected to analysis on 10%o denaturing acrylamide gels. The gel was analyzed by Western blot (21) and probed with the SB66
antibody. Lanes 1 and 2 are proteins complexes with HIVEN3c and HIVEN3m oligonucleotides, respectively. The location of p59v-rel is indicated
(p59).
Anti-v-ref Pre-immune'
GO
P59v_-'e
ICLt]1"_J
Pf
IL
E
<I-
z z
-2i LIJ
c
p59-
D E
qr v ll.r v
m CQ co PQ
i
l
Proc. Natl. Acad. Sci. USA 88 (1991) 1787
To determine which of these proteins corresponded to
v-rel, immunoprecipitates with monoclonal antibody 33 were
made from the NPB4 cell line. Immunoprecipitated protein
was then analyzed by 2D gel electrophoresis. As can be seen
in Fig. 3C, p59v`re and three other minor proteins (labeled G,
H, and I) were specifically precipitated. However, the three
minor species did not bind to the wild-type NF-KB oligonu-
cleotide (Fig. 3B). Fig. 3D is a control immunoprecipitation
carried out with hypoxanthine/aminopterin/thymidine
(HAT) medium alone to show nonspecific background pro-
teins. Comparison of Fig. 3 B with C shows definitively that
p59vrel binds to the wild-type NF-KB oligonucleotide. In
addition, it appears that only one isoform of the protein
participates in the binding.
Further confirmation of v-rel binding was obtained by
immunoblot analysis of the DNAP complex. NPB4 lysate
was used to form protein-DNA complexes on wild-type
(HIVEN3c) or mutant (HIVEN3m) oligonucleotides. Eluted
protein was subjected to analysis on denaturing polyacryl-
amide gels and Western blots. The probe, in this case, was
SB66, which recognizes p68c-rel, p59vrel, and several other
cross-reactive species of40-50 kDa (Fig. 1D, lane 3). Fig. 3E
is an example of such a blot. p59v`re and several other
cross-reactive species of40-50 kDa can be seen (Fig. 3E, lane
1). Comparatively low amounts of binding to the mutant
oligonucleotide (HIVEN3m) are detected in this assay as
expected (Fig. 3E, lane 2).
These data definitively demonstrate that p59v`re is a mem-
ber ofa set ofproteins that are able to bind to the NF-KB site.
As demonstrated, several other proteins are also involved in
this interaction (encircled and bracketed proteins in Fig. 3B).
These proteins were not found in immunoprecipitates from
NPB4 cells using monoclonal antibody 33, which is specific
for v-rel and not proteins in the lower molecular mass range
(Fig. 1D, lane 2). Clearly, it will be of interest to determine
ifpolyclonal antibody SB66 recognizes proteins such as D, E,
or F (Fig. 3B) since it recognizes proteins in that molecular
mass range in immunoblot analysis (Fig. 1D, lane 3). Given
the apparent molecular mass of these proteins (40-50 kDa),
it is possible that one of them is the rel-related p5O/KBF-1/
NF-KB.
The data presented demonstrate conclusively that v-rel
from a REV-T-transformed lymphoid cell line is involved
with other proteins in binding to the NF-KB site. We have not
yet shown that v-rel binds directly to DNA. However, Kieran
et al. (10) have shown that a truncated form of in vitro-
translated v-rel interacts with the KBF-1 site. Purified v-rel
should be tested for its ability to bind directly to DNA. It will
be of interest to determine if c-rel is involved in an interaction
at the NF-KB site. Because there is no normal cell counter-
part to the NPB4 cell line, direct comparison of v-rel and c-rel
was precluded. However, preliminary analysis of extracts
from normal bursal lymphoid cells revealed binding activity
that resulted in protein-DNA complexes that did not appear
to comigrate with those formed with NPB4 extracts. At least
a portion of these bursal cell complexes were reactive with a
c-rel-specific peptide antibody, suggesting that c-rel is also
able to interact with the NF-KB binding site. Determination
of the specificity of v-rel and c-rel binding and the functional
consequences of that binding on transcription will undoubt-
edly lead to a better understanding of transformation by the
rel gene.
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